Intelligent Bio Solutions
INBS
8 hedge funds and large institutions have $416K invested in Intelligent Bio Solutions in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
2.83% less ownership
Funds ownership: 10.41% → 7.58% (-2.8%)
11% less funds holding
Funds holding: 9 → 8 (-1)
40% less capital invested
Capital invested by funds: $697K → $416K (-$281K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$30K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.34K |
| 4 |
Barclays
London,
United Kingdom
|
+$373 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$127K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$20.4K |
| 3 |
CW
Curio Wealth
Annapolis,
Maryland
|
-$669 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $325K | +$30K | +11,397 | +9% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $47.8K | -$20.4K | -7,769 | -27% |
|
3
Vanguard Capital Management
Malvern,
Pennsylvania
| $13.3K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $13.2K | +$14.1K | +5,363 | +1,442% |
|
5
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $9.08K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $7.53K | +$5.34K | +2,030 | +162% |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $460 | – | – | – |
|
|
8
Barclays
London,
United Kingdom
| $326 | +$373 | +142 | New |
|
|
9
Alyeska Investment Group
Chicago,
Illinois
| – | -$127K | -37,956 | Closed |
|
|
CW
10
Curio Wealth
Annapolis,
Maryland
| – | -$669 | -200 | Closed |
|
INBS Hedge Fund Activity: Q2 2026 in Review
8 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Intelligent Bio Solutions (INBS) for Q2 2026, worth a combined $416K — down 40% from $697K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of INBS and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, adding an estimated $30K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $127K sold.
- 8 institutional investors held Intelligent Bio Solutions (INBS) as of Q2 2026, down from 9 in Q1 2026.
- Funds reported $416K of Intelligent Bio Solutions stock for Q2 2026, down 40% quarter-over-quarter.
- 1 fund opened new Intelligent Bio Solutions positions in Q2 2026 and 2 closed out, a net change of -1 holder.
- The largest Intelligent Bio Solutions buyer in Q2 2026 was Armistice Capital, an estimated $30K added.
- The largest Intelligent Bio Solutions seller in Q2 2026 was Alyeska Investment Group, an estimated $127K sold.
Based on aggregated 13F filings for Q2 2026.